Similar articles for PMID: 22432846

Year	Number of Results
2002	1
2004	1
2005	3
2006	7
2007	7
2008	5
2009	12
2010	29
2011	28
2012	41
2013	37
2014	36
2015	26
2016	21
2017	22
2018	14
2019	30
2020	20
2021	14
2022	9

1

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Derosa G, Maffioli P. Derosa G, et al. Curr Clin Pharmacol. 2012 Aug;7(3):214-28. doi: 10.2174/157488412800958686. Curr Clin Pharmacol. 2012. PMID: 22432846 Review.

2

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.

3

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A. Tzefos M, et al. Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Ann Pharmacother. 2012. PMID: 22232377 Review.

4

The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.

Guo XH. Guo XH. Curr Med Res Opin. 2016;32(1):61-76. doi: 10.1185/03007995.2015.1103214. Epub 2015 Nov 11. Curr Med Res Opin. 2016. PMID: 26439329 Review.

5

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B. Deacon CF, et al. Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Diabetes Obes Metab. 2012. PMID: 22471248 Review.

6

Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.

7

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group. Buse JB, et al. Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8. Lancet. 2009. PMID: 19515413 Clinical Trial.

8

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N. Mikhail N. Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845. Expert Opin Investig Drugs. 2008. PMID: 18491986 Review.

9

Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.

Ottney A. Ottney A. Am J Health Syst Pharm. 2013 Dec 1;70(23):2097-103. doi: 10.2146/ajhp130081. Am J Health Syst Pharm. 2013. PMID: 24249759 Review.

10

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. Madsbad S, et al. Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Diabetes Obes Metab. 2011. PMID: 21208359 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed